Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15042495 | 0.94 | ALDH1A1 (0.36) | ALDH1A1KMT2AS1PR1S1PR3KDM4E | |
| SCHEMBL15042598 | 0.91 | SLC6A5 (0.35) | ALDH1A1TRPV6KMT2ASLC6A5SMN1; SMN2 | |
| SCHEMBL15042635 | 0.89 | MPO (0.38) | ALDH1A1KMT2ASCN8A | |
| SCHEMBL15042476 | 0.89 | S1PR2 (0.37) | ALDH1A1KMT2AS1PR2S1PR1S1PR3 | |
| SCHEMBL15042553 | 0.88 | ALDH1A1 (0.36) | ALDH1A1KMT2AS1PR2S1PR1S1PR3 | |
| SCHEMBL15042494 | 0.88 | SLC6A5 (0.35) | KMT2ASLC6A5SMN1; SMN2CASP6KDM4E | |
| SCHEMBL15022595 | 0.86 | S1PR2 (0.48) | SLC6A5S1PR2S1PR1S1PR3LPAR2 | |
| SCHEMBL15042515 | 0.85 | KMT2A (0.33) | TRPV6KMT2ASLC6A5S1PR2S1PR1 | |
| SCHEMBL15746766 | 0.84 | SCN8A (0.34) | TRPV6KMT2ASLC6A5SMN1; SMN2SCN8A | |
| SCHEMBL15042607 | 0.82 | ALDH1A1 (0.39) | ALDH1A1KMT2AS1PR2S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828973-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140221317-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8741875-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130157982-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221317-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR1, S1PR3, S1PR2 | ALDH1A1 3552/4885TRPV6 234/4885KMT2A 4028/4885 |
| US-20130157982-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR1, S1PR3, S1PR2 | ALDH1A1 3552/4885TRPV6 234/4885KMT2A 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.